EchoGo® Heart Failure vs TeraRecon Aorta.CT
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, EchoGo® Heart Failure, is designed to detect HFpEF using echocardiograms, providing diagnostic insights for clinical decision-making. In contrast, Tool B, TeraRecon Aorta.CT, focuses on the automatic segmentation and labeling of aortic anatomical landmarks from CT angiography scans to aid in patient management and procedure planning. While both are FDA-cleared AI tools in cardiology, they address distinct clinical problems using different imaging modalities.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGou00ae Heart Failure is an AI platform designed to analyze routine echocardiograms to detect Heart Failure with preserved Ejection Fraction (HFpEF), providing insights to support clinical decisions. TeraRecon Aorta.CT is an AI-powered Software as a Medical Device (SaMD) that automatically segments and labels anatomical landmarks of the Aorta from CT Angiography scans, aiding in patient management and procedure planning.
EchoGou00ae Heart Failure analyzes routine echocardiogram video clips, specifically a single apical 4-chamber view. TeraRecon Aorta.CT processes CT Angiography with contrast DICOM images.
EchoGou00ae Heart Failure offers seamless integration with existing workflows and IT stacks, delivering automated structured reports via DICOM workflow to PACS within 20 minutes. TeraRecon Aorta.CT outputs DICOM result files for other DICOM-compliant systems and integrates with TeraRecon Intuition and Eureka Clinical AI.
EchoGou00ae Heart Failure is reimbursable via CPT code 0932T for outpatient analysis, with a national Medicare average of $316 per analysis, and is covered by Medicare and select commercial insurers. For inpatient settings, it may be eligible for NTAP reimbursement up to $1,023.75 per acute hospital inpatient stay. For TeraRecon Aorta.CT, pricing information requires direct contact with the company.
EchoGou00ae Heart Failure is clinically validated with 90% sensitivity and 86% specificity for HFpEF detection. TeraRecon Aorta.CT aids in patient management and procedure planning by providing automatic 3D segmentation and labeling of the Aorta, but it explicitly states it does not alter original input data or provide a diagnosis.